Wolverine Trading
CRVS icon

Wolverine Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Wolverine Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,600
Closed -$49K – 5702
2025
Q2 		$49K Sell
12,600
-25,300
-67% -$92.1K ﹤0.01% 4349
2025
Q1 		$128K Buy
+37,900
New +$179K ﹤0.01% 4150
2024
Q4 		– Sell
-27,500
Closed -$142K – 5350
2024
Q3 		$142K Buy
+27,500
New +$98.7K ﹤0.01% 4243
2023
Q3 		– Sell
-19,400
Closed -$43.3K – 4583
2023
Q2 		$43.3K Buy
19,400
+6,900
+55% +$14.3K ﹤0.01% 3982
2023
Q1 		$10K Buy
+12,500
New +$9.76K ﹤0.01% 4072
2022
Q2 		– Sell
-13,700
Closed -$22K – 4671
2022
Q1 		$22K Buy
+13,700
New +$25.1K ﹤0.01% 5234
2021
Q4 		– Sell
-31,700
Closed -$200K – 6031
2021
Q3 		$200K Buy
+31,700
New +$93.8K ﹤0.01% 5345

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return